Literature DB >> 6291832

Correlation between angiotensin converting enzyme inhibition and the acute hypotensive response to MK 421 in essential hypertension.

B Jackson, B P McGrath, C I Johnston.   

Abstract

1. The acute hormonal and hypotensive effects of MK 421 (10 mg p.o.) were assessed by a double-blind randomized trial in twelve subjects with essential hypertension. The study was performed during a normal and low salt intake. 2. Plasma angiotensin converting enzyme (ACE) activity was maximally inhibited by 57 (s.e.m. = 4)% of control activity at 4-8 h. Plasma ACE was still depressed at 24 h by 10% of control activity but had returned to normal by 32 h. 3. Sodium depletion did not alter basal plasma ACE activity, nor change the degree of inhibition of MK 421. 4. Plasma angiotensin II was depressed during ACE inhibition, but no change in circulating bradykinin was detected. Reciprocal rises occurred in plasma renin and angiotensin I levels with a time course similar to ACE inhibition. 5. All subjects showed a fall in their blood pressure, maximal between 6-8 h. Mean arterial pressure fell 12 (s.e.m. = 5) mmHg on the normal sale intake and 16 (s.e.m. = 3) mmHg on the low salt diet, at 8 h. 6. Blood pressure and angiotensin converting enzyme activity changes were significantly correlated (r = 0.86, n = 12).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6291832

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol Suppl        ISSN: 0143-9294


  7 in total

Review 1.  Drug treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1988       Impact factor: 9.546

2.  Enalapril (MK421) activation in man: importance of liver status.

Authors:  I Larmour; B Jackson; R Cubela; C I Johnston
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

3.  Studies on the antihypertensive effect of single doses of the angiotensin converting enzyme inhibitor ramipril (HOE 498) in man.

Authors:  R O Böhm; M A van Baak; K H Rahn
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

5.  Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension.

Authors:  C I Johnston; B J Jackson; I Larmour; R Cubella; D Casley
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

Review 6.  An overview of the clinical pharmacology of enalapril.

Authors:  R O Davies; H J Gomez; J D Irvin; J F Walker
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

7.  Enalapril in essential hypertension: a comparative study with propranolol. Enalapril in Hypertension Study Group (UK).

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.